Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMUS 001 in metastatic pancreatic cancer
2016-004155-67Phase 2Unknown
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Jun 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of paclitaxel, gemcitabine, oxaliplatin, fluorouracil and folinic acid in pancreatic cancer (PC) (2 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
paclitaxelgemcitabineoxaliplatinfluorouracilfolinic acid
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2016-004155-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004155-67.